Show simple item record

AuthorEl Kahlout, Reham Awni
AuthorCoyle, Peter V.
AuthorDargham, Soha R.
AuthorChemaitelly, Hiam
AuthorKacem, Mohamed Ali Ben Hadj
AuthorAl-Mawlawi, Naema Hassan Abdulla
AuthorGilliani, Imtiaz
AuthorYounes, Nourah
AuthorAlKanaani, Zaina
AuthorAlKhal, Abdullatif
AuthorALKuwari, Einas
AuthorJeremijenko, Andrew
Available date2022-09-01T09:33:44Z
Publication Date2022-01
Publication NamePLoS ONE
Identifierhttp://dx.doi.org/10.1371/journal.pone.0262897
CitationCoyle, P. V., El Kahlout, R. A., Dargham, S. R., Chemaitelly, H., Kacem, M. A. B. H., Al-Mawlawi, N. H. A., ... & Abu-Raddad, L. J. (2022). Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. PloS one, 17(1), e0262897.‏
URIhttp://hdl.handle.net/10576/33630
AbstractThis study investigated the performance of a rapid point-of-care antibody test, the BioMedomics COVID-19 IgM/IgG Rapid Test, in comparison with a high-quality, validated, laboratory-based platform, the Roche Elecsys Anti-SARS-CoV-2 assay. Serological testing was conducted on 709 individuals. Concordance metrics were estimated. Logistic regression was used to assess associations with seropositivity. SARS-CoV-2 seroprevalence was 63.5% (450/709; 95% CI 59.8%-67.0%) using the BioMedomics assay and 71.9% (510/709; 95% CI 68.5%-75.2%) using the Elecsys assay. There were 60 discordant results between the two assays, all of which were seropositive in the Elecsys assay, but seronegative in the BioMedomics assay. Overall, positive, and negative percent agreements between the two assays were 91.5% (95% CI 89.2%-93.5%), 88.2% (95% CI 85.1%-90.9%), and 100% (95% CI 98.2%-100%), respectively, with a Cohen’s kappa of 0.81 (95% CI 0.78–0.84). Excluding specimens with lower (Elecsys) antibody titers, the agreement improved with overall, positive, and negative percent concordance of 94.4% (95% CI 92.3%-96.1%), 91.8% (95% CI 88.8%-94.3%), and 100% (95% CI 98.2%-100%), respectively, and a Cohen’s kappa of 0.88 (95% CI 0.85–0.90). Logistic regression confirmed better agreement with higher antibody titers. The BioMedomics COVID-19 IgM/IgG Rapid Test demonstrated good performance in measuring detectable antibodies against SARS-CoV-2, supporting the utility of such rapid point-of-care serological testing to guide the public health responses and vaccine prioritization. © 2022 Coyle et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Languageen
PublisherPublic Library of Science
Subjectcoronavirus disease 2019
young adult
point of care testing
TitleAssessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
TypeArticle
Issue Number1
Volume Number17
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record